Related Experiment Video
Updated: May 8, 2026
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Targeting the immune system in the treatment of non-small-cell lung cancer
Deepa Rangachari1, Julie R Brahmer
1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins Hospital, Bunting-Blaustein Cancer Research Building 1, 1650 Orleans St., Room 186, Baltimore, MD, 21287, USA, drangac1@jhmi.edu.
Opinion Statement:
Non-small-cell lung cancer (NSCLC) remains the most common cause of cancer-related death worldwide. Traditional cytotoxic agents and their attendant toxicities have remained the mainstay of systemic therapy for this disease, until now. With the identification of novel molecular and immune cancer-specific aberrancies, molecular agents and immunotherapies have garnered increasing attention as attractive targets, with the potential for improved outcomes while mitigating systemic toxicities seen with traditional cytotoxic agents. Despite a longstanding interest in immunotherapy for the treatment of NSCLC, results of prior studies of therapeutic vaccines have failed to show durable or convincingly meaningful clinical responses. However, newer trials of therapeutic vaccines and checkpoint inhibitors have yielded more promising results. In particular, the checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed death-1 (PD-1) pathway have shown meaningful clinical responses with manageable toxicities. Large phase III studies are underway, the results of which have the potential to revolutionize the way in which we care for patients with NSCLC. More studies also are needed to investigate the potentially synergistic effects of traditional and immune-based therapies. Given their unique antineoplastic effects, novel immune-specific clinical endpoints also are actively being investigated.
Insights
New immunotherapies, including checkpoint inhibitors targeting CTLA-4 and PD-1, show promise for treating non-small-cell lung cancer (NSCLC). These novel treatments offer improved outcomes and manageable toxicities compared to traditional chemotherapy.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Non-small-cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
- Traditional cytotoxic chemotherapy for NSCLC is associated with significant toxicities.
- Emerging molecular and immune targets offer potential for improved efficacy and reduced side effects.
Purpose of the Study:
- To review the evolving landscape of systemic therapy for NSCLC.
- To highlight the advancements in immunotherapy, particularly checkpoint inhibitors.
- To discuss the potential of novel immune-based therapies and their combination with traditional treatments.
Main Methods:
- Review of recent clinical trials and scientific literature on NSCLC treatment.
- Focus on immunotherapies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death-1 (PD-1) pathways.
- Exploration of synergistic effects between traditional and immune-based therapies.
Main Results:
- Prior therapeutic vaccines for NSCLC showed limited clinical responses.
- Newer immunotherapies, including checkpoint inhibitors (CTLA-4 and PD-1), demonstrate promising clinical responses with manageable toxicities.
- Large-scale phase III studies are ongoing, with potential to transform NSCLC patient care.
Conclusions:
- Immunotherapy, particularly checkpoint inhibitors, represents a significant advancement in NSCLC treatment.
- Further research is needed to explore combination therapies and novel immune-specific endpoints.
- These novel approaches hold the potential to revolutionize NSCLC management and improve patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy